what is the new glp 1 drug GLP-1 Medications for Weight Loss With FDA approval of Wegovy

This tripartite interaction plays a central role in the pathogenesis of various diseases, particularly metabolic disorders such as type 2 diabetes and obesity (Figure 2)

Presented for research literature review only Oguchi M et al

4.1.2 Smart nanocarriers for acidic microenvironments The acidic environment of tumor cells, resulting from aberrant metabolism, influences their behavior and the effectiveness of chemotherapy

About Daiichi Sankyo Group Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose "to contribute to the enrichment of quality of life around the world." In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs